A Study of Sovilnesib in Subjects With Ovarian Cancer
Public ClinicalTrials.gov record NCT06084416. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b Dose Optimization Study of Sovilnesib (an Oral KIF18A Inhibitor) in Subjects With Selected Advanced Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a phase 1b study to assess the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of sovilnesib at different dose levels to establish the optimal dose of sovilnesib in subjects with selected advanced solid tumors.
Study identification
- NCT ID
- NCT06084416
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 150 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 4, 2024 (Actual)
- Primary completion
- Nov 2027 (Estimated)
- Completion
- Dec 2027 (Estimated)
- Last update posted
- Oct 13, 2026
2024 – 2027
United States locations
- U.S. sites
- 11
- U.S. states
- 10
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| The University of Alabama at Birmingham | Birmingham | Alabama | 35294 | Recruiting |
| University of Arkansas for Medical Sciences | Little Rock | Arkansas | 72205 | Active, not recruiting |
| Hoag Memorial Hospital | Newport Beach | California | 92663 | Active, not recruiting |
| Georgia Cancer Center Augusta University | Atlanta | Georgia | 30912 | Recruiting |
| Johns Hopkins Hospital | Baltimore | Maryland | 21287 | Active, not recruiting |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | Active, not recruiting |
| Roswell Park Comprehensive Cancer Center | Buffalo | New York | 14263 | Recruiting |
| Icahn School of Medicine at Mount Sinai | New York | New York | 10128 | Active, not recruiting |
| OU Health Stephenson Cancer Center | Oklahoma City | Oklahoma | 73117 | Recruiting |
| MUSC Hollings Cancer Center | Charleston | South Carolina | 29020 | Active, not recruiting |
| Fred Hutchinson Cancer Center | Seattle | Washington | 98109 | Active, not recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06084416, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 13, 2026 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06084416 live on ClinicalTrials.gov.